Arbutus Biopharma Corp ABUS

Healthcare Biotechnology

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company. The Company is leveraging its virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV) infection. Its HBV product pipeline includes Imdusiran and AB-101. Imdusiran is its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic product candidate. AB-101 is an oral PD-L1 inhibitor that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for.

NDAQ:ABUS - Post by User

Arbutus Biopharma Corp

Bullboard Posts

Comment by TimeScapeon Feb 21, 2014 9:54am

352 Views

Post# 22234174

RE:RE:RE:RE:RE:RE:What is going on?

Actually, Tekmira is nowhere close to an all time high. After allowing for the share consolidations (1 for 10 in total) years ago, the all time high is around $120 Cdn back when the company was called Inex, so the current price is less then 1/5 of the all time high. As I mentioned a few days ago, there was some technical resistance at about $20, but it got through that pretty quickly, and the next resistance point is about $40. Given the size of the potential markets the company is addressing, that doesn't seem unreasonable. Would be a market cap of around $800 million. News regarding the agriculture applications would be big in driving the stock price higher. No idea when we might be hearing about that.

Bullboard Posts

Critical raw materials pioneer drives Europe’s clean energy transition